Titre du document / Document title

Leflunomide improves psoriasis in patients with psoriatic arthritis : An in-depth analysis of data from the TOPAS study

Auteur(s) / Author(s)

NASH Peter ⁽¹⁾ ; THACI Diamant ⁽²⁾ ; BEHRENS Frank ⁽²⁾ ; FALK Franziska ⁽³⁾ ; KALTWASSER J. Peter ⁽²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Nambour General Hospital and University of Queensland, Brisbane, AUSTRALIE
⁽²⁾ Klinikum der J.W.-Goethe-Universitat, Frankfurt/Main, ALLEMAGNE
⁽³⁾ Sanofi-Aventis Deutschland GmbH, Bad Soden, ALLEMAGNE

Résumé / Abstract

Background: Leflunomide has shown promise in the treatment of psoriasis. Objective:To provide an in-depth analysis of the effect of leflunomide on psoriasis in patients with psoriatic arthritis (PsA). Methods: 190 patients with plaque psoriasis (at least 3% skin involvement) and active PsA were randomized to double-blind treatment with leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally) or placebo for 24 weeks. Results: As previously reported, leflunomide resulted in a significantly higher Psoriatic Arthritis Response Criteria response rate than placebo (58.9 vs. 29.7%; p < 0.0001). Significant differences in favor of leflunomide were also observed in the Psoriasis Area and Severity Index (PASI 50 in 30.4% of patients vs. 18.9% for placebo; p = 0.05), target lesion response (46.4 vs. 25.3%; p = 0.0048), combined skin and joint response (27.2 vs. 8.9%; p < 0.0001), Dermatology Life Quality Index (improvement of 1.9 points vs. 0.2; p = 0.0173) and certain SF-36 subdomains. Dermatological responses were observed at the earliest examination (4 weeks) and increased throughout the 24-week study. Conclusion: Once-daily oral leflunomide is an effective and convenient treatment for PsA and plaque psoriasis.

Revue / Journal Title

Dermatology   ISSN 1018-8665 

Source / Source

2006, vol. 212, n^o3, pp. 238-249 [12 page(s) (article)] (42 ref.)

Langue / Language

Anglais

Editeur / Publisher

Karger, Basel, SUISSE  (1992) (Revue)

Mots-clés anglais / English Keywords

Diseases of the osteoarticular system ; Spondylarthropathy ; Inflammatory joint disease ; Skin disease ; Enzyme ; Oxidoreductases ; Prostaglandin-endoperoxide synthase ; Isoxazole derivatives ; Enzyme inhibitor ; Treatment ; Chronic ; Immunosuppressive agent ; Antirheumatic agent ; Non steroidal antiinflammatory agent ; Quality of life ; Dermatology ; Severity score ; Oral administration ; Chemotherapy ; Human ; Psoriatic arthritis ; Psoriasis ; Leflunomide ;

Mots-clés français / French Keywords

Système ostéoarticulaire pathologie ; Spondylarthropathie ; Rhumatisme inflammatoire ; Peau pathologie ; Enzyme ; Oxidoreductases ; Prostaglandin-endoperoxide synthase ; Isoxazole dérivé ; Inhibiteur enzyme ; Traitement ; Chronique ; Immunodépresseur ; Antirhumatismal ; Antiinflammatoire non stéroïde ; Qualité vie ; Dermatologie ; Indice gravité ; Voie orale ; Chimiothérapie ; Homme ; Rhumatisme psoriasique ; Psoriasis ; Léflunomide ;

Mots-clés espagnols / Spanish Keywords

Sistema osteoarticular patología ; Espondilartropatia ; Reumatismo inflamatorio ; Piel patología ; Enzima ; Oxidoreductases ; Prostaglandin-endoperoxide synthase ; Inhibidor enzima ; Tratamiento ; Crónico ; Inmunodepresor ; Antireumático ; Antiinflamatorio no esteroide ; Calidad vida ; Dermatología ; Indicio gravedad ; Vía oral ; Quimioterapia ; Hombre ; Reumatismo psoriásico ; Psoriasis ; Leflunomida ;

Mots-clés d'auteur / Author Keywords

Leflunomide ; Psoriasis ; Psoriatic arthritis ; Psoriasis Area and Severity Index (PASI) ; Dermatology Life Quality Index (DLQI) ;

Localisation / Location

INIST-CNRS, Cote INIST : 4530, 35400015346332.0070